Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App




Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections

By LabMedica International staff writers
Posted on 15 Jul 2026

Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. More...

Delays in profiling gram-negative organisms, which are frequently associated with antimicrobial resistance, can postpone appropriate treatment and hinder infection control. A newly launched panel now delivers one-hour detection of gram-negative bloodstream pathogens and resistance markers from positive blood cultures, expanding rapid testing options in Europe.

QIAGEN has introduced the CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel for use on the QIAstat-Dx platform in Europe. The assay detects 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance markers from positive blood cultures in about one hour. It complements the recently launched QIAstat-Dx BCID GPF Plus AMR Panel in Europe, extending coverage across gram-positive bacteria, gram-negative bacteria, fungi, and key resistance mechanisms.

QIAstat-Dx is a cartridge-based molecular system that integrates sample preparation, molecular analysis, and result interpretation in a streamlined workflow. The platform delivers results in about one hour from positive blood cultures, enabling laboratories to generate clinically relevant insights. The combined detection of pathogen targets and resistance markers supports antimicrobial stewardship and infection control efforts.

Used together, the gram-negative and gram-positive/fungal panels provide detection of 33 pathogen targets and 28 antimicrobial resistance markers for comprehensive bloodstream infection testing on the same platform. The QIAstat-Dx BCID GN Plus AMR Panel is CE-IVDR certified and available in applicable European markets, and regulatory review by the U.S. Food and Drug Administration (FDA) is underway. The addition builds on a QIAstat-Dx menu that also includes respiratory, gastrointestinal, and meningitis/encephalitis panels.

Gram-negative pathogens are among the leading causes of bloodstream infection and are frequently associated with antimicrobial resistance. The growing burden of beta-lactam resistance driven by extended-spectrum beta-lactamase and carbapenemase-producing organisms underscores the need for rapid and accurate detection. As of the end of 2025, more than 5,200 QIAstat-Dx instruments were placed in over 100 countries, supporting broad access to the expanded bloodstream infection testing menu.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Led by Professor Sherry Chan Kit-wa (middle), the HKUMed research team provides the first large-scale Chinese population evidence to support reviewing Hong Kong’s long-term blood-monitoring requirements for clozapine use. (Photo courtesy of HKUMed)

Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine

Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA).... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.